Methylation of promoter-associated CpG islands appears to be a potential way by which tumor suppressor genes are inactivated in cancer. Using Southern blot analysis, we have studied the methylation of several genes in glioblastoma multiforme (GBM), trying to determine their contribution to tumorigenesis. Genes studied included the estrogen receptor (ER), N33, the candidate tumor-suppressors P15, P16 and HIC1 and a control gene, c-abl. Hypermethylation of N33, ER, HIC1, P16, P15 and c-abl were found in 61%, 59%, 60%, 5%, 2% and 0% of GBM respectively. HIC1 methylation was detected in normal brain as well, but appeared to be more extensive in tumors. ER and N33 methylation were signi®cantly more frequent in tumors from individuals over the age of 40 (70% and 88% vs 36% and 14%). In addition, there was a strong association between ER and N33 methylation, which were concordant in 81% of the cases (P50.01). ER and N33 methylation in GBM may therefore appear as a result of shared etiologic factors, which may relate in part to aging cell populations in the brain.
Introduction
Alterations in DNA methylation constitute some of the most consistent molecular changes in tumorigenesis (Counts and Goodman, 1995; Jones, 1996) . Hypermethylation of selected gene promoters may be especially critical in this process (Issa et al., 1997a; Baylin et al., 1997) . In normal cells, CpG islands in the promoter region of genes are protected from methylation, with the exception of transcriptionally silent genes on the inactive X chromosome and some imprinted genes (Cross and Bird, 1995) . Hypermethylation of normally unmethylated CpG islands in tumors is strongly associated with silencing of gene expression (Eden and Cedar, 1994) and may constitute an alternative mechanism to coding region mutations for irreversible inactivation of tumor suppressor genes (TSG) (Sakai et al., 1991; Herman et al., 1994 Herman et al., , 1995 Gonzalez-Zulueta et al., 1995) .
Gliomas are the most common primary tumors of the human central nervous system and glioblastoma multiforme (GBM) is the most malignant form among them. Molecular alterations described in GBM involve overexpression of oncogenes (Furnari et al., 1995) (EGFR, VEGF, Ras, PDGF, PDGFR), mutational inactivation of TSG (Steck et al., 1997; Li et al., 1997; Furnari et al., 1995) (P53, P16, RB, PTEN/ MMAC1) and hypermethylation of the HIC1, P16 and P15 genes (Makos et al., 1993a; Herman et al., 1995 Herman et al., , 1996 Costello et al., 1996; Fueyo et al., 1996) . The factors that lead to promoter methylation in GBM and the interactions between dierent methylation events remain poorly de®ned. To clarify these issues, we have studied the methylation status of six CpG island associated genes (ER, HIC1, N33, P15, P16, c-abl) in 45 primary GBM. Our data indicate a remarkable association between ER and N33 methylation which are concordant in 81% of the cases, and which are both more frequent in tumors of older patients.
Results

Methylation status of multiple CpG islands in normal brain
We initially examined the methylation status of six CpG island-associated promoters in four samples of nonneoplastic brain obtained at autopsy. The six genes chosen for this study were: The estrogen receptor gene (ER), which is methylated in normal colon as a function of age (Issa et al., 1994) and which is hypermethylated in a large number of neoplasms; HIC1 (Hypermethylated in Cancer 1), a candidate tumor-suppressor gene cloned because of the presence of a CpG island on 17p13.3 which is hypermethylated in many neoplasms (Wales et al., 1995) ; The N33 gene, which was recently identi®ed from an area of frequent allelic losses in prostate cancer and which is hypermethylated in colon cancer (MacGrogan et al., 1996) . The P15 and P16 genes which function as inhibitors of cell cycle progression and have tumor-suppressor properties (Kamb, 1995) ; and as a control, the c-abl gene. Using Southern blot analysis of DNA restricted with methylation-sensitive enzymes and hybridized with 5' region probes, ®ve of the genes (ER, N33, P15, P16 and c-abl) had no detectable (less than 3%) methylation in normal brain (Figure 1 and data not shown). Surprisingly however, some HIC1 methylation was detectable in all four samples (Figure 1c) , as indicated by the presence of bands of 6 kb or larger. In this limited series of patients who ranged in age from 30 ± 93 years of age, we found no appreciable association between age and HIC1 methylation in normal brain.
Methylation status of six CpG island associated promoters in GBM
We next examined the methylation status of all six genes in GBM (examples in Figure 1 and data not shown). In each case, the relative percentage of the methylation-related bands was determined using densitometry on the phosphorimager blots. For all genes except HIC1, a tumor was considered methylated when more than 10% of its DNA failed to cut with a methylation-sensitive enzyme. Because GBM grow as in®ltrative masses, it is very dicult to obtain samples of tumors that are free of contamination by normal cells. Thus, we assume that in most of the cases where methylation appears to be partial, this is due to lack of methylation in contaminating tissues. Nevertheless, it is possible that true partial methylation exists in some tumors. For statistical purposes, we analysed the data based on methylation as both a continuous variable and a categorical variable (with 410% as positive), but we believe the latter may be more biologically appropriate.
We studied a total of 45 dierent tumors but, due to limited DNA quantities, results were not available for all the genes in each tumor. For the ER gene, methylation averaged 24.6% in 44 samples (range 2 ± 80%) and 59% of these (26/44) were considered to be hypermethylated (410% methylation) (Figure 1a ). N33 methylation averaged 37.4% in 38 samples (range 0 ± 94%) and 61% (23/38) were considered to be hypermethylated (410% methylation) (Figure 1b ). P16 and P15 methylation was only observed in one GBM, which displayed hypermethylation of both loci simultaneously (the frequency of P16 and P15 methylation was 4.5% (1/19) and 2.3% (1/44) respectively (data not shown). Homozygous deletion of P16 exon 1 was evident in 4/19 (21%) samples, while homozygous deletion of P15 was found in 3/44 (7%) cases (data not shown). The c-abl gene was unmethylated in all tumors, and was used to con®rm complete digestion of the DNA samples with the restriction enzymes (data not shown).
In a previous study of HIC1 methylation status in neural tumors, we found hypermethylation of all NotI sites in and around the region of the gene in virtually all low-and mid-grade astrocytomas but only in 50% of high grade gliomas (Makos et al., 1993a) . In the present study, a range of methylation was seen in the majority of tumors ( Figure 1c ) and these patterns must be put into perspective with the methylation status of HIC1 in normal brain. Such controls were not available from the tumor patients and, in our original study, control DNA from paired samples originally provided as tumor and surrounding brain were subsequently found to represent peripheral blood cell DNA. To address this issue, we measured the intensity of the 12 and 16 kb bands observed in Figure 1c (which re¯ect extensive methylation at the HIC1 locus) and compared the 45 tumors to the four normal brain samples examined. HIC1 methylation averaged 45.2% in GBMs, compared to 20.7% in normal brain (P50.01 using the t-test). Twenty-seven out of 45 tumors (60%) had HIC1 methylation values higher than the average for normal +2 standard deviations and are therefore likely to be hypermethylated (when compared to normal). This data thus suggests that Promoter methylation in GBM. Methylation status in normal brain tissue (Normal) and GBM was determined by restricting DNA using methylation-sensitive enzymes, followed by Southern hybridization with probes containing the promoter or 5' region of the tested gene. The presence of bands of higher molecular weight in GBM samples (denoted by arrows) represent methylation of these restriction sites. (a) Representative Southern blot of ER methylation in normal brain and GBMs. DNA was restricted using EcoRI (¯ank) and NotI (methylation-sensitive) and probed with part of exon 1 of the ER gene. ER is unmethylated in normal brain, but hypermethylated in three out of the four tumors shown. (b) Representative Southern blot of N33 methylation in normal brain and GBMs. DNA was restricted using HindIII (¯ank) and SacII (methylation-sensitive) and probed with a 5' region N33 probe. N33 is unmethylated in normal brain, but hypermethylated in three out of the four tumors shown. (c) Representative Southern blot of HIC1 methylation in normal brain and GBMs. DNA was restricted using EcoRI (¯ank) and NotI (methylation-sensitive) and probed with the VNTR probe YNZ22, which is 2 ± 3 kb upstream of the HIC1 gene. In this analysis, most normal samples have two (unmethylated) allelic bands at 4 ± 5 kb, depending on the length of the VNTR. HIC1 was partially methylated in normal brain as shown by bands of 6.0, 8.0 and 12 kb. In tumors, the intensity of methylation appears to be increased. In addition, hypermethylation of all NotI sites within the EcoRI¯ank gave a band of 16 kb which was observed in one of the four GBMs shown HIC1 methylation precedes tumorigenesis and becomes more intense in a subset of GBMs but, because of the limited number of normal brain samples analysed and the unavailability of paired normal brain/brain tumor samples our data may not accurately re¯ect the methylation changes of HIC1 in GBM.
Age related methylation of ER and N33
To investigate the factors that might in¯uence promoter methylation in GBM, we next correlated clinical patient characteristics with the various methylation events observed. There was no correlation between gender and methylation of any of the genes examined. However, there was a striking association between age at diagnosis and the incidence of ER and N33 methylation. A regression analysis using methylation as a continuous variable showed a strong association between ER methylation and age (R=0.45, P50.002), as well as between N33 methylation and age (R=0.60, P50.0001). When considered as a categorical variable, the frequency of ER and N33 methylation appeared to change dramatically after age 40 (Table 1 and Figure 2 ). Among patients in a younger age group (440 years), ER was methylated in ®ve out of 14 cases (36%) and N33 was methylated in two out of 14 cases (14%). By contrast, in the group of patients over 40 years of age, ER was methylated in 21 out of 30 cases (70%, P=0.03 by w 2 analysis when compared to the younger age group), and N33 was methylated in 21 out of 24 cases (88%, P50.0001 by Fisher's t-test when compared to the younger age group). By contrast, there was no association between age and HIC1 hypermethylation using either methylation as a continuous variable (R=0.06, P=0.67), or as a categorical variable (Table 1) .
No other factor appeared to be associated with methylation. In particular, there was no association between methylation and histologic subtype of GBM and the median survival was the same in all methylation categories.
Concordant methylation of ER and N33
The availability of methylation data on several genes in the same tumors allowed us to study potential interactions between these various events. Thirty-seven tumors had data available for all of ER, N33 and HIC1 methylation. Using regression analysis of methylation measured as a continuous variable, there was a strong association between ER and N33 methylation (R=0.63, P50.0001), but no association between HIC1 and either ER or N33 methylation. As shown in Figure 3 , when methylation is used as a categorical variable, 19 out of the 37 tumors (51%) were methylated at ER and N33 simultaneously, 11 (30%) displayed neither methylation event and only seven (19%) were discordant for ER and N33 methylation (P=0.001 using Fisher's exact t-test of a 262 table ER+ and7 vs N33+ and7). In a separate analysis based on the individual frequencies of methylation (59.1% for ER and 60.5% for N33), out of 37 cases, we would expect 13 cases ER+N33+, nine cases ER+N337, nine cases ER7N33+ and six cases ER7N337. The respective measured frequencies were 19, 4, 3 and 11, (w 2 =7.52, P=0.058), indicating again, a signi®cant dierence in the number of concordant cases (19 expected, 30 observed). 2/5 (40%) 7/9 (78%) 7/9 (78%) 3/6 (50%) 4/8 (50%) 4/8 (50%) Figure 2 Methylation of ER and N33 in GBM are age-related events. All tumors were studied by Southern blot analysis as shown in Figure 1 . The percentage of tumors methylated at ER, N33 and HIC1 is indicated for both the younger patients (440 years, represented by an open square) and the older patients (440 years, represented by a solid square). ER and N33 methylation was signi®cantly more frequent in the older age group, while HIC1 hypermethylation (see text for de®nition) was not dierent in the two groups Figure 3 Concordant methylation of ER and N33. The distribution of ER and N33 methylation in GBMs was plotted in a pie graph. Of 37 total cases analysed, 19 (51%) had both ER and N33 methylation, 11 (30%) had neither gene methylated, four (11%) had only ER methylation and three (6%) had only N33 methylation. Thus the total concordance for ER and N33 methylation is 81% (P=0.001)
Because both genes are methylated more frequently in tumors from older patients, we wondered whether this concordance is related simply to age. In younger patients (440), 11 out of 14 (79%) tumors were concordant for ER and N33 methylation while, in older patients (440), 19 out of 23 (83%) tumors were similarly concordant (P=0.8 for a dierence in concordance between the two age groups). While the numbers are small, these data suggest that ER and N33 methylation track together, independent of the age of the patient.
Discussion
In this study, we have established the patterns of methylation changes involving several CpG island associated promoters in primary GBM. These include (i) partial HIC1 methylation in normal brain and increased methylation in tumors, (ii) a frequent agerelated and concordant methylation of ER and N33 and (iii) a less frequent methylation of P15 and P16, which is most likely related to the fact that P16 is frequently inactivated by other mechanisms (such as deletion and mutation) in glial tumors (Herman et al., 1995; Costello et al., 1996; Fueyo et al., 1996) .
HIC1 is now known to exhibit partial methylation in normal cells in a tissue speci®c way ranging from no methylation in sites such as blood and bone marrow cells (Issa et al., 1997b) , ®broblasts, skin and colon (Wales et al., 1995) , to methylation of only 2 ± 3 of the most 5' NotI sites in kidney (Makos et al., 1993b) and bronchial epithelium (Vertino et al., 1993) , to a most interesting pattern of 50% completely methylated and 50% unmethylated alleles in breast (Issa JPJ, unpublished observations) and prostate epithelium (Morton et al., 1996) . Our present data suggest that cells of the central nervous system are also characterized by partial methylation at the HIC1 locus. It now becomes important to determine whether the observed methylation aects neural cells, non-neural cells or both. Unfortunately, cell culture systems can introduce arti®cial changes in methylation due to cell selection or de novo methylation. The most reliable way to study this issue would then be using in situ methylation analysis, a technique that is not available at present.
While the functional signi®cance of this tissuespeci®c CpG island methylation is not known, we have previously observed an analogous situation involving the CpG island of the imprinted IGF2 gene (partial methylation in normal tissues, full methylation in many cancers) (Issa et al., 1996b) , raising the possibility that HIC1 may also display tissue-speci®c imprinting. Neuroblastomas, as well as a fraction of GBM, appear to have less methylation than normal brain (Makos et al., 1993a) and this may be due to loss of the methylated allele in the tumor, true demethylation, or cancer initiation in a totally unmethylated cell. The functional signi®cance of HIC1 methylation in GBM will have to await careful expression studies in normal and neoplastic brain tissues.
The high frequency of ER methylation observed here may have important implications for the biology of GBMs. Estrogens appear to modulate cell growth and dierentiation in the central nervous system (Ramirez and Zheng, 1996) . ER is expressed in normal brain and its transcript has been detected in dierent types of cultured glial cells (Santagati et al., 1994) . Recent studies of ER in several tumor types have indicated that this molecule may have tumor suppressor properties (Ma et al., 1993; Garcia et al., 1992) . Diminished or absent ER expression has been associated tightly with methylation of a CpG island in the ER promoter in multiple cell types; Methylation of the ER gene has previously been seen in 100% of colon cancers (Issa et al., 1994) , 80% of leukemias (Issa et al., 1996c) , 25% of lung cancers (Issa et al., 1996a) and 25% of ER negative breast cancers (Lapidus et al., 1996) . Reexpression of ER inhibits cell growth in various cancer cell lines including breast (Zajchowski et al., 1993; Jiang and Jordan, 1992) , colon (Issa et al., 1994) , neuroblastoma (Ma et al., 1993) and HeLa cells (Maminta et al., 1991) . Our present data suggest that ER methylation (and presumed loss of expression) may play a role in the pathogenesis of GBMs as well.
Strikingly, ER methylation was signi®cantly more frequent in tumors of older patients. In the colon, partial methylation of ER can be observed in normal tissues, and increases with age (Issa et al., 1994) . In normal brain, however, we have not observed partial methylation of the ER gene. Nevertheless, our ®ndings could be explained by age-related methylation in a small population of glial cells that is not detectable by Southern blot analysis (i.e. representing less than 3% of nucleated cells in the brain since 3% is the approximate limit for methylation detection in our studies) that becomes predisposed to GBM tumorigenesis in the process. Alternatively, triggering factors (genetic predisposition, carcinogen exposure) may be signi®cantly dierent between the young and older group of patients with GBM and these factors may then in¯uence the incidence of ER methylation, as we have previously observed in a rodent model of lung tumorigenesis (Issa et al., 1996a) . Interestingly, studies of peripheral blood lymphocytes from GBM patients have shown a higher frequently of chromatid breaks and gaps after g-irradiation compared with cells from normal controls (Bondy et al., 1996) . This indirect evidence may suggest that glial cells from patients with GBM may also be genetically susceptible to speci®c carcinogen exposures.
Perhaps the most surprising ®ndings in this study relate to the frequency and patterns of N33 methylation. N33, which shares homology with the oligosaccharyl transferase enzyme, is frequently methylated in colorectal tumors (MacGrogan et al., 1996) and becomes methylated in normal colonic tissues as a function of age (Issa, JPJ, unpublished observations) . While the functional signi®cance of N33 methylation in GBM remains unclear, its association with age and its striking concordance with ER methylation provide interesting clues as to the mechanism of cancer-related methylation. The fact that these two distinct genes, with no apparent homology (including in the promoter region) and on two dierent chromosomes, become methylated in the same subset of tumors suggests that their methylation arises as a function of a shared etiologic factor. The speci®city of this association between ER and N33 is evidenced by the fact that, even though HIC1 methylation is very common in GBMs, there is no correlation between ER or N33 methylation and HIC1 methylation and no correlation between HIC1 methylation and age. Furthermore, Thrombospondin-1, a gene which is methylated in 40% of GBMs (Li Q, submitted 1998 ) also shows no concordant methylation with either ER or N33 methylation (data not shown). Thus the relationship between ER and N33 methylation appears to be unique. Since both genes (but not HIC1 or Thrombospondin-1) become methylated as a function of age in normal colon, it may be that their concordant methylation in GBM relates to the cell of origin of these tumors. As discussed above, it is possible that a small population of glial cells (too small to be detected by Southern blot analysis) displays age-related methylation of multiple genes, as observed in the colon, and that these cells give rise to the subset of GBMs with simultaneous ER and N33 methylation. This would explain why this concordance is also present in tumors of young individuals, even though ER and N33 methylation is rare in these patients. Alternatively, it is also possible that ER and N33 are both`hypersensitive' to carcinogen-induced promoter methylation, perhaps as a result of a unique local chromatin context and that their concordant methylation relates to dierential carcinogen exposures among patients with GBM. Whatever its mechanism, our data suggests that there may be families of genes which behave in similar ways with regards to age and carcinogenesis related promoter methylation.
In summary, we have shown that promoter methylation is a frequent event in GBMs and that it aects multiple genes. Our data suggests important interplays between methylation in normal appearing tissues, aging and tumorigenesis. Future studies should address the functional signi®cance of some of the methylation events observed in GBM.
Materials and methods
Tissue samples
Primary GBM samples were obtained at surgical resection and normal brain tissues were obtained from a brain tissue bank derived from autopsies performed at the Johns Hopkins Hospital. The collection of these tissue samples were approved by the Joint Committee on Clinical Investigation of the Johns Hopkins Hospital in accordance with the policies of the Department of Health and Human Services.
Southern blot analysis
DNA was extracted using standard techniques. Five micrograms of genomic DNA was restricted with 100 units of the appropriate restriction enzyme (New England Biolabs) according to the manufacturer's recommendations. For HIC1 ER and c-abl, we used EcoRI (¯ank) and NotI (methylation sensitive). For N33, P15, P16 and c-abl, we used HindIII (¯ank) and EagI (methylation sensitive). The DNA fragments were separated in 1% agarose gels, blotted to a nylon membrane (Bio-Rad) and hybridized with the various probes described below. The blots were then exposed in a PhosphorImager (Molecular Dynamics) and the results were analysed using the Image Quant Software (Molecular Dynamics).
Hybridization probes
Probes used for the analysis of promoter methylation of HIC1 (Makos et al., 1993a) , N33 (MacGrogan et al., 1996) , P16 (Herman et al., 1995) and c-abl (Issa et al., 1996b) were as described in the referenced articles. For the P15 gene, a 495 bp SpE I/SpH I fragment was excised from clone BCE4 containing the promoter region of the human P15 gene and used as a probe. For the ER gene, a 428 bp probe was ampli®ed from genomic DNA using primers AACCTCGGGCTGTGCTCTTTTTCCAG (upper) and AGTAGCATCAGCGGGCTCGGAGACAC (lower). All probes were labeled by random priming (Boehringer Mannheim) using 32 P-dCTP (Amersham).
Statistics
All statistical tests were performed using the Excel software (Microsoft).
